Inactive Instrument
Checkmate Pharmaceuticals, Inc. Stock
Stocks
CMPI
US1628181083
Biotechnology & Medical Research
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 12/12/2018 | |
Robert Landry
DFI | Director of Finance/CFO | 62 | 31/05/2022 |
James Wooldridge
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/10/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Nouhad Husseini
BRD | Director/Board Member | - | 31/05/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/5/22 | Issuer sale | Director | 36,778 | 0.1700% | ||
| 31/5/22 | Issuer sale | Chief Financial Officer | 278,480 | 1.2874% | ||
| 31/5/22 | Issuer sale | Chief Executive Officer | 279,437 | 1.2919% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +0.38% | - | - | 231M | |
| -2.11% | -1.68% | +44.52% | +95.15% | 66.93B | |
| -0.23% | -4.45% | +30.39% | +73.64% | 61.97B | |
| +1.67% | +2.47% | -11.23% | +388.34% | 28.27B | |
| -1.05% | -4.43% | +30.56% | +10.07% | 24.59B | |
| +0.34% | -6.78% | -7.27% | -17.99% | 24.3B | |
| +0.43% | -3.37% | +14.85% | -19.29% | 19.41B | |
| -3.03% | -2.29% | +185.12% | +334.07% | 16.77B | |
| -1.94% | -4.94% | -5.29% | +495.65% | 14.18B | |
| -2.28% | -4.90% | +43.64% | +155.21% | 13.91B | |
| Average | -0.82% | -3.46% | +36.14% | +168.32% | 30.04B | |
| Weighted average by Cap. | -0.84% | -3.06% | +33.46% | +133.67% |
Employees
31
